Gan & Lee Pharmaceuticals.: Announcement on the implementation of cancellation of part of restricted stock repurchase plan for 2022 restricted stock incentive plan.
Announcement on the "Improve Efficiency and Return to Profit" Action Plan for the Year 2024.
Announcement on GMP inspection before EU EMA listing approval
Announcement on the receipt of Mexican drug registration approval for insulin glargine injections (pre-filled pens)
Announcement on the resignation of a director
Legal Opinion of Beijing Zhonglun Law Firm on the 2023 Annual General Meeting of Shareholders of Ganli Pharmaceutical Co., Ltd.
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Announcement on the cancellation bill for the 2023 Annual General Meeting of Shareholders
2023 Annual General Meeting of Shareholders Meeting Materials
Notice on the completion of changes in industrial and commercial registration information
Accounting Services Selection and Hiring System
Special report of the board of directors on the self-inspection of the independence of independent directors
Notice on changing registered capital and amending the “Articles of Association”
Notice on convening the 2023 Annual General Meeting of Shareholders
2023 Internal Control Evaluation Report
2023 Board Audit Committee Performance Report
Report on the performance of supervisory duties by the Audit Committee of the Board of Directors of Ganli Pharmaceutical Co., Ltd. on the 2023 Accounting Firm
Announcement on the company's participation in the national centralized drug procurement (insulin special continuation) to win the bid
Announcement on the completion of the Phase I clinical trial of GZR18 tablets in China
Notice on Using Idle Own Funds for Cash Management
No Data